Author: Yeleswaram, Swamy; Smith, Paul; Burn, Timothy; Covington, Maryanne; Juvekar, Ashish; Li, Yanlong; Squier, Peg; Langmuir, Peter
Title: Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment Cord-id: eu7f0zjm Document date: 2020_6_23
ID: eu7f0zjm
Snippet: Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma levels of pro-inflammatory cytokines, which can result in cytokine storm, followed by massive immune cell infiltration into the lungs leading to alveolar damage, decreased lung function, and rapid pr
Document: Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma levels of pro-inflammatory cytokines, which can result in cytokine storm, followed by massive immune cell infiltration into the lungs leading to alveolar damage, decreased lung function, and rapid progression to death. As many of the elevated cytokines signal through Janus kinase (JAK)1/JAK2, inhibition of these pathways with ruxolitinib has the potential to mitigate the COVID-19–associated cytokine storm and reduce mortality. This is supported by preclinical and clinical data from other diseases with hyperinflammatory states, where ruxolitinib has been shown to reduce cytokine levels and improve outcomes. The urgent need for treatments for patients with severe disease support expedited investigation of ruxolitinib for patients with COVID-19.
Search related documents:
Co phrase search for related documents- activator transducer and adaptive immune response: 1, 2, 3, 4
- activator transducer and adaptive immune response innate: 1, 2
- activator transducer and lung function: 1, 2, 3
- activity profile and acute ards respiratory distress syndrome: 1
- activity profile and adaptive immune response: 1
- activity profile and adaptive immune response innate: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adaptive immune response innate: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and additional patient: 1, 2
- acute ards respiratory distress syndrome and long term infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- acute ards respiratory distress syndrome and lymphopenia improvement: 1, 2
- acute ards respiratory distress syndrome and macrophage inflammatory protein: 1, 2, 3, 4, 5
- adaptive immune response and long term infection: 1, 2, 3
- adaptive immune response and lung function: 1, 2, 3, 4
- adaptive immune response and macrophage inflammatory protein: 1
- adaptive immune response innate and long term infection: 1
- adaptive immune response innate and lung function: 1, 2, 3
- additional patient and long term infection: 1
Co phrase search for related documents, hyperlinks ordered by date